Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vericel Corporation - Common Stock (NQ:VCEL)

35.59 +0.25 (+0.71%)
Streaming Delayed Price Updated: 10:56 AM EDT, Jul 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vericel Corporation - Common Stock

< Previous 1 2 3 4 5 Next >
Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025
From Vericel Corporation
Via GlobeNewswire
VERICEL CORP (NASDAQ:VCEL) – A Strong Growth Stock with Technical Breakout Potential
VERICEL CORP (NASDAQ:VCEL) shows strong growth fundamentals and a technical breakout pattern, making it a stock to watch in the biotech sector. 
Via Chartmill
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025
From Vericel Corporation
Via GlobeNewswire
VERICEL CORP (NASDAQ:VCEL) – A Strong Growth Stock with Technical Breakout Potential
VERICEL CORP (NASDAQ:VCEL) shows strong revenue and earnings growth, backed by a solid balance sheet and a promising technical breakout pattern. 
Via Chartmill
Earnings Scheduled For May 8, 2025
Via Benzinga
Where Vericel Stands With Analysts
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
What 7 Analyst Ratings Have To Say About Vericel
Via Benzinga
What Analysts Are Saying About Vericel Stock
Via Benzinga
VERICEL CORP (NASDAQ:VCEL) – A Strong Growth Stock with a Technical Setup
VERICEL CORP (NASDAQ:VCEL) shows strong growth potential with solid profitability and a promising technical setup, making it a stock worth watching. 
Via Chartmill
Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025
From Vericel Corporation
Via GlobeNewswire
Beyond The Numbers: 5 Analysts Discuss Vericel Stock
Via Benzinga
Earnings Preview For Vericel
Via Benzinga
The Analyst Verdict: Vericel In The Eyes Of 7 Experts
Via Benzinga
Expert Ratings For Vericel
Via Benzinga
Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at Multiple Upcoming Investor Conferences
From Vericel Corporation
Via GlobeNewswire
Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results
From Vericel Corporation
Via GlobeNewswire
Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025
From Vericel Corporation
Via GlobeNewswire
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025
From Vericel Corporation
Via GlobeNewswire
Vericel Stock Sees RS Rating Shoot Higher
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79. 
Via Investor's Business Daily
Smaller Cap Biotechs Are In Season: How Are We Doing?
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
Vericel Reports Third Quarter 2024 Financial Results
From Vericel Corporation
Via GlobeNewswire
Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024
From Vericel Corporation
Via GlobeNewswire
Vericel Announces FDA Approval and Commercial Availability of MACI Arthro
From Vericel Corporation
Via GlobeNewswire
Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
From Vericel Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.